CURRENT MANAGEMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY
Abstract
Currently, there are several treatment options that can be offered to patients with PCV, including photodynamic therapy, administration of anti-vascular endothelial growth factor (anti-VEGF) agents, thermal laser, or a combination of these. Currently, PDT has the highest potential as it is a therapeutic option targeted at the choroid. Although PDT has been recognized as the standard treatment for PCV due to its high regression rate and good functional outcomes, it also has some disadvantages. Initially, PDT treatment for PCV was found to have complications such as acute vision loss and massive subretinal haemorrhage. These complications have been reduced with the introduction of anti-VEGF agents in PCV management. There is no specific anti-VEGF agent that has shown superiority over others. Thermal laser is an effective and relatively cheaper modality of treatment compared to PDT. Thermal laser plays an important role in the management of PCV in extrafoveal, peripapillary, and peripheral areas. Combination therapy is an attractive option for patients with PCV which can provide better polyp closure and visual outcomes, and also a decrease in complication rates compared to monotherapy.
Keywords
Full Text:
PDFReferences
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1-8.
Sahu Y, Chaudhary N, Joshi M, Gandhi A. Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices. Int Ophthalmol. 2021;41(2):753-765. doi:10.1007/s10792-020-01620-0
Fenner BJ, Cheung CMG, Sim SS, et al. Evolving treatment paradigms for PCV. Eye (Basingstoke). 2022;36(2):257-265. doi:10.1038/s41433-021-01688-7
Koh AHC, Expert PCV Panel, Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33(4):686-716. doi:10.1097/IAE.0b013e3182852446
Anantharaman G, Sheth J, Bhende M, et al. Polypoidal choroidal vasculopathy: Pearls in diagnosis and management. Indian J Ophthalmol. 2018;66(7):896-908. doi:10.4103/ijo.IJO_1136_17
Baek J, Lee JH, Jeon S, Lee WK. Choroidal morphology and short-term outcomes of combination photodynamic therapy in polypoidal choroidal vasculopathy. Eye. 2019;33(3):419-427. doi:10.1038/s41433-018-0228-7
Azuma K, Okubo A, Nomura Y, et al. Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Sci Rep. 2020;10(1):8337. doi:10.1038/s41598-020-65346-w
Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2011;151(4):594-603.e1. doi:10.1016/j.ajo.2010.10.030
Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. British Journal of Ophthalmology. 2008;92(1):70-73. doi:10.1136/bjo.2007.122283
Chan WM, Lam DSC, Lai TYY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology. 2004;111(8):1576-1584. doi:10.1016/j.ophtha.2003.12.056
Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy. Jpn J Ophthalmol. 2007;51(4):270-277. doi:10.1007/s10384-007-0452-3
Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2005;243(10):973-979. doi:10.1007/s00417-005-1139-4
Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55(1):39-44. doi:10.1007/s10384-010-0886-x
Kurashige Y, Otani A, Sasahara M, et al. Two-Year Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2008;146(4):513-519.e2. doi:10.1016/j.ajo.2008.05.025
Otani A, Sasahara M, Yodoi Y, et al. Indocyanine Green Angiography: Guided Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2007;144(1):7-14.e1. doi:10.1016/j.ajo.2007.03.014
Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic Therapy with Verteporfin for Polypoidal Choroidal Vasculopathy of the Macula. Ophthalmologica. 2004;218(3):193-201. doi:10.1159/000076844
Asano-Shimizu K, Asano S, Murata H, et al. Early changes of vascular lesions and responses to combined photodynamic therapy in patients with polypoidal choroidal vasculopathy. Int Ophthalmol. 2020;40(6):1335-1345. doi:10.1007/s10792-020-01299-3
SPAIDE RF, DONSOFF I, LAM DL, et al. TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY. Retina. 2002;22(5):529-535. doi:10.1097/00006982-200210000-00001
Lee SY, Kim JG, Joe SG, Chung H, Yoon YH. The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy. Korean Journal of Ophthalmology. 2008;22(2):92. doi:10.3341/kjo.2008.22.2.92
Fan NW, Lau LI, Chen SJ, Yang CS, Lee FL. Comparison of the effect of reduced-fluence photodynamic therapy with intravitreal bevacizumab and standard-fluence alone for polypoidal choroidal vasculopathy. Journal of the Chinese Medical Association. 2014;77(2):101-107. doi:10.1016/j.jcma.2013.10.012
Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of Treatment Parameters on Selectivity of Verteporfin Therapy. Investigative Opthalmology & Visual Science. 2006;47(1):371. doi:10.1167/iovs.05-0354
Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP. COMBINED REDUCED FLUENCE PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina. 2012;32(7):1280-1288. doi:10.1097/IAE.0b013e318236e835
Yamashita A, Shiraga F, Shiragami C, Ono A, Tenkumo K. One-Year Results of Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2010;149(3):465-471.e1. doi:10.1016/j.ajo.2009.09.020
Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004;88(6):809-815. doi:10.1136/bjo.2003.032466
Tong JP, Chan WM, Liu DTL, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456-462. doi:10.1016/j.ajo.2005.10.012
Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye. 2012;26(3):426-433. doi:10.1038/eye.2011.324
Hara C, Sawa M, Sayanagi K, Nishida K. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina. 2016;36(1):37-45. doi:10.1097/IAE.0000000000000767
Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. SWITCHING TO INTRAVITREAL AFLIBERCEPT INJECTION FOR POLYPOIDAL CHOROIDAL VASCULOPATHY REFRACTORY TO RANIBIZUMAB. Retina. 2014;34(11):2192-2201. doi:10.1097/IAE.0000000000000236
Inoue M, Arakawa A, Yamane S, Kadonosono K. SHORT-TERM EFFICACY OF INTRAVITREAL AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina. 2014;34(11):2178-2184. doi:10.1097/IAE.0000000000000229
Yamamoto A, Okada AA, Kano M, et al. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. Ophthalmology. 2015;122(9):1866-1872. doi:10.1016/j.ophtha.2015.05.024
Chaikitmongkol V, Cheung CMG, Koizumi H, Govindahar V, Chhablani J, Lai TYY. Latest developments in polypoidal choroidal vasculopathy: Epidemiology, etiology, diagnosis, and treatment. Asia-Pacific Journal of Ophthalmology. 2020;9(3):260-268. doi:10.1097/01.APO.0000656992.00746.48
Teo KYC, Jordan-Yu JM, Tan ACS, et al. Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. British Journal of Ophthalmology. 2022;106(7):987-993. doi:10.1136/bjophthalmol-2020-318354
Qu J, Cheng Y, Li X, Yu L, Ke X. EFFICACY OF INTRAVITREAL INJECTION OF CONBERCEPT IN POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina. 2016;36(5):926-937. doi:10.1097/IAE.0000000000000875
Gemmy Cheung CM, Yeo I, Li X, et al. Argon Laser With and Without Anti-Vascular Endothelial Growth Factor Therapy for Extrafoveal Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2013;155(2):295-304.e1. doi:10.1016/j.ajo.2012.08.002
Nishijima K, Takahashi M, Akita J, et al. Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2004;137(4):770-773. doi:10.1016/j.ajo.2003.09.059
Kwok A, Lai T, Chan C, Neoh E, Lam D. Polypoidal choroidal vasculopathy in Chinese patients. British Journal of Ophthalmology. 2002;86(8):892-897. doi:10.1136/bjo.86.8.892
Lee M, Yeo I, Wong D, Ang C. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye. 2009;23(1):145-148. doi:10.1038/sj.eye.6702955
Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2000;238(9):752-759. doi:10.1007/s004170000180
Yuzawa M, Mori R, Haruyama M. A Study of Laser Photocoagulation for Polypoidal Choroidal Vasculopathy. Jpn J Ophthalmol. 2003;47(4):379-384. doi:10.1016/S0021-5155(03)00042-X
Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-1464. doi:10.1097/IAE.0b013e31824f91e8
Tan CS, Ngo WK, Chen JP, et al. EVEREST study report 2: Imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. British Journal of Ophthalmology. 2015;99(5):624-628. doi:10.1136/bjophthalmol-2014-305674
Oishi A, Kojima H, Mandai M, et al. Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results. Am J Ophthalmol. 2013;156(4):644-651.e1. doi:10.1016/j.ajo.2013.05.024
Lee WK, Iida T, Ogura Y, et al. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study. JAMA Ophthalmol. 2018;136(7):786. doi:10.1001/jamaophthalmol.2018.1804
Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149(6):947-954.e1. doi:10.1016/j.ajo.2009.12.038
Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;150(1):48-54.e1. doi:10.1016/j.ajo.2010.02.008
Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol. 2010;94(8):1045-1051. doi:10.1136/bjo.2009.173120
Moon DRC, Lee DK, Kim SH, You YS, Kwon OW. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean Journal of Ophthalmology. 2015;29(4):226. doi:10.3341/kjo.2015.29.4.226
DOI: https://doi.org/10.26618/aimj.v6i2.10953
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Fredy Ciputra
Al-Iqra Medical Journal: Jurnal Ilmiah Kedokteran under by Creative Commons Attribution-NoDerivatives 4.0 International License.